Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience Maria Queralt Salas, a,b,⁎ Alberto Mussetti, a,b Carme Muñóz, a Adaia Albasanz-Puig, b Beatriz Patiño, a Laura Jimenez Prat, a Carlota Gudiol, b Rocío Parody, a,b and Anna Sureda a,b,c Methods: Allogeneic stem cell transplantation recipients who received concomitant tacrolimus and isavuconazole from September 2017 to September 2018 were included
Methods: Tacrolimus and sirolimus trough serum concentrations were measured up to twice weekly for up to 4 weeks
00970-17 Abstract We evaluated the interaction between isavuconazole and tacrolimus among 55 organ transplant recipients
All SOTR who received ISA for treatment of a fungal infection (FI) at our center from December 2017 to January 2021 were included
Isavuconazole is a moderate inhibitor of Cytochrome P4503A4, and tacrolimus Isavuconazole (ISA) is a newer antifungal used in patients with history of hematologic malignancies and hematopoietic transplant and cellular therapies (HM/TCT)
There was considerable interpatient variability in the magnitude of the drug interaction and tacrolimus doses should not be adjusted uniformly but, rather, be guided by therapeutic drug monitoring
Clancy, +4 authors Hong Nguyen Published 2017 Medicine Two retrospective studies which included 55 and 26 SOT recipients that received isavuconazole as prophylaxis, and had TDM performed for both isavuconazole and tacrolimus, concluded that the interaction between these drugs was more significant after liver transplantation, that the impact of isavuconazole on tacrolimus levels varied between Isavuconazole is unstudied as prophylaxis in organ transplant recipients
5%, p < 0
5%) patients Our findings therefore indicate that isavuconazole was a useful antifungal agent for IFI prophylaxis following lung transplantation
1-3 However, premature discontinuation of voriconazole AFP occurs in up to 40% of patients due to adverse events (AE), predominately voriconazole-associated hepatotoxicity
Isavuconazole is a moderate inhibitor of Cytochrome P4503A4, and tacrolimus Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience oral mucosa, eyes and liver was diagnosed in April 2020
Rifabutin, an alternative rifamycin, though less Isavuconazole prophylaxis among solid organ transplant recipients: effectiveness and drug interaction with tacrolimus
Isavuconazole is a moderate inhibitor of Cytochrome P4503A4, and tacrolimus 10
We evaluated the interaction between isavuconazole and tacrolimus among The aim of this study was to determine the extent of interaction between tacrolimus and itraconazole in lung transplant recipients and the efficacy of itraconazole prophylaxis
Letermovir is an antiviral agent recently approved for primary CMV prophylaxis during the first 14 weeks after allogeneic HSCT ()
Isavuconazole prophylaxis was discontin-ued We evaluated the interaction between isavuconazole and tacrolimus among 55 organ transplant recipients
3-fold in the area under the curve of plasma concentration of sirolimus and tacrolimus (18,- 20)
5: 12-15: 3-4: Open in a separate window
Methods: We performed a retrospective study including all adult SOT recipients with proven or probable invasive mold disease (IMD) that received Methods: Allogeneic stem cell transplantation recipients who received concomitant tacrolimus and isavuconazole from September 2017 to September 2018 were included
For example, in many programs trimethoprim-sulfamethoxazole (TMP-SMX) is given to all transplant recipients who do not have sulfa The continuing increase in the number of patients treated with transplantation procedures is attested by a worldwide activity of more than 150 000 grafts per year, including solid-organ transplants and haematopoietic stem-cell transplants
In this post-hoc analysis of two prospective clinical trials (VITAL and SECURE), the safety and efficacy of isavuconazole in According to the published studies, isavuconazole has a significantly lower risk of interaction with tacrolimus, and is less hepatotoxic than voriconazole
Its current FDA-approved indications include the management of invasive aspergillosis as well as mucormycosis, though the latter indication is supported by limited clinical data
1Transplant Institute, NYU Langone Health, New York, NY; and the 2Cardiothoracic Surgery, NYU Langone Health, New York, NY
Expand
Keywords: Aspergillus; Candida; Mucorales A recent prospective randomized clinical trial for antifungal prophylaxis of liver transplant recipients based on prior identified risk factors for IA failed to Nakamura R, Pon D
Background: Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RIC)
We aimed to determine the magnitude of effect of isavuconazole administration on tacrolimus and sirolimus C/D ratios in allogeneic hematopoietic stem cell transplant
Isavuconazole (ISA) is an alternative treatment for Aspergillus spp
Abstract We evaluated the interaction between isavuconazole and tacrolimus among 55 organ transplant recipients
Fifty-five consecutive solid organ transplant (kidney, liver, lung, and heart) recipients were assessed retrospectively to investigate the need for empiric dose
Hematopoietic cell transplantation (HCT) is associated with a high risk of invasive fungal infections (IFIs)
Isavuconazole prophylaxis among solid organ transplant recipients: effectiveness and drug interaction with tacrolimus | Semantic Scholar Corpus ID: 211257139
There was considerable interpatient variability in the magnitude of the drug interaction and tacrolimus doses should not be adjusted uniformly but, rather, be guided by therapeutic drug monitoring
Tacrolimus was empirically dose reduced due
8% rate of infection with nontuberculous mycobacteria (NTM) in the year after transplant
GVHD prophylaxis Tacrolimus + methotrexate * 26 Isavuconazole prophylaxis was started at a median of 7 days after HCT (IQR, 7 to 8 days; range, 5 to 11 days) and continued according to protocol for a median of 90 days (IQR, 87 to 91 days; range, 1 to 93 days)
Introduction Isavuconazole is increasingly being used for antifungal prophylaxis during stem cell transplantation
We established a population pharmacokinetic (pop PK) model of intravenous (i
We analyzed the use of isavuconazole (ISA) as treatment or prophylaxis for invasive fungal disease (IFD) in children with hemato-oncologic diseases
We evaluated the interaction between isavuconazole and tacrolimus among 55 organ transplant recipients
3-fold in the area under the curve of plasma concentration of sirolimus and tacrolimus (18,– 20)
Voriconazole, a broad-spectrum triazole active against Candida and Aspergillus species, has been
The available clinical experience, nevertheless, is scarce
In a drug interaction study, isavuconazole given at the approved dosing regimen for 5 days totaled led to a 2